(firstQuint)Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors.

 This study is single arm study with DS-6051b in approximately 9 subjects with advanced solid malignant tumors harboring either a ROS1 or NTRK fusion gene.

 Safety and tolerability, pharmacokinetics (PK), MTD/RP2D (maximum tolerated dose/recommended phase 2 dose) and preliminary efficacy of DS-6051b will be evaluated.

.

 Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors@highlight

This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of DS-6051b in Japanese subjects with advanced solid malignant tumors harboring either a ROS1 or NTRK fusion gene.

